Skip to content

JACS JACS Offering Costs Charged To Additional Paid In Capital

Offering Costs Charged To Additional Paid In Capital at other companies

Sionna Therapeutics, Inc. Common Stock logo
Sionna Therapeutics, Inc. Common StockSION
$0-100%
Cal-Maine Foods logo
Cal-Maine FoodsCALM
$1.7M
Neuropace, Inc. logo
Neuropace, Inc.NPCE
$0-100%
CEP
Cantor Equity Partners II, Inc. Class A Ordinary ShareCEPT
$5.3M+19,713%
MidCap Financial Investment Corporation logo
MidCap Financial Investment CorporationMFIC
$300K
CEP
Cantor Equity Partners II, Inc. Class A Ordinary ShareCEPT
$5.3M+19,713%

Other financials

Income statement

See full
Operating income-$168.3K+18.4%
Net income$2.0M-11.6%
EPS (diluted)$0.07-12.5%

Balance sheet

See full
Cash & equivalents$393.5K-48.0%
Total equity$52.5K-91.0%
Total assets$245.2M+3.8%

Cash flow

See full
Operating cash flow-$128.3K+33.7%

Valuation

See full
Market cap$314.69M+3.3%
P/E35.5×

Returns & leverage

See full
Return on equity2,785.2%
Current ratio1.1×-1.2×

Where this comes from

Reported directly by JACS in its filing.

Tagged under the XBRL concept jacs:OfferingCostsChargedToAdditionalPaidInCapital.

The official record: JACS’s 10-K, filed March 20, 2026, on SEC EDGAR. View the filing →

Ask your AI about JACS's offering costs charged to additional paid in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is JACS's offering costs charged to additional paid in capital?
JACS (JACS) reported offering costs charged to additional paid in capital of $557.74K in Q4 2024.
What does offering costs charged to additional paid in capital mean?
Represents the portion of offering costs that are directly deducted from equity rather than being expensed through the income statement. This accounting treatment is standard for costs directly attributable to the issuance of shares. It helps investors reconcile changes in equity and understand the net impact of issuance costs.